ExCEEd Orphan
ExCEEd Orphan is a private specialty pharmaceutical services company that supports rare disease drug manufacturers with distribution, market access, and pharmacovigilance services across Central and Eastern Europe, operating through entities in Croatia and the Czech Republic.
- Company typePrivate
- Founded2018
- HeadquartersPrague, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingServices
ExCEEd Orphan firmographics
Firmographics- Name
- ExCEEd Orphan
- Legal name
- ExCEEd Orphan s.r.o.
- Website
- https://exceedorphan.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ExCEEd Orphan is a private specialty pharmaceutical services company that supports rare disease drug manufacturers with distribution, market access, and pharmacovigilance services across Central and Eastern Europe, operating through entities in Croatia and the Czech Republic.
- Ownership category
- akta.pro rank
ExCEEd Orphan industry classification
Industry- Product category
- Orphan Drug Distribution & Pharmacovigilance Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where ExCEEd Orphan is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
ExCEEd Orphan business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Marketing or Sales
ExCEEd Orphan product offering
Product offeringCore offering
ExCEEd Orphan performs multiple successful launches of rare disease medications (orphan drugs) in Central & Eastern European countries. The company provides specialized regional distribution and pharmacovigilance / drug safety services to support orphan drug commercialization across the CEE region, acting as a niche market-entry and lifecycle partner for pharmaceutical manufacturers of rare disease therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Orphan Drug Launch & Distribution Services (CEE)
Companies that use ExCEEd Orphan
Customer profileIdeal customer profiles1 record
ExCEEd Orphan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ExCEEd Orphan competitors and assessment
Company assessmentDirect peers
- Swedish Orphan Biovitrum (SOBI): Global orphan and rare-disease specialist with established CEE commercial infrastructure, competing for the same sponsor mandates and distribution rights that ExCEEd Orphan targets.
- Recordati Rare Diseases (Orphan Europe): Specialty division of Recordati focused on orphan drugs across Europe; directly competes with ExCEEd Orphan for CEE distribution agreements and licensing partnerships.
Broad incumbents
- BioMarin Pharmaceutical: Large rare-disease biopharma with its own CEE commercialization apparatus; competes as a sponsor who may or may not outsource CEE launches to specialists like ExCEEd Orphan.
- Alexion (AstraZeneca Rare Disease): Rare-disease unit of AstraZeneca operating broadly in the same therapeutic categories; potential sponsor partner but also a competitor that may internalize CEE distribution.
Emerging players
- Ultragenyx Pharmaceutical: Emerging rare-disease biotech that has historically used regional partners for European commercialization; representative of the sponsor customer type ExCEEd Orphan serves.
- Dipharma: European specialty/CDMO pharma with rare-disease exposure; comparable in scale and regional focus to ExCEEd Orphan and a potential adjacent competitor for niche CEE pharma mandates.
Regional players
- Polpharma: One of the largest CEE-headquartered pharmaceutical manufacturers with broad regional reach; competes for CEE pharma services and distribution mandates across therapeutic areas including rare diseases.
- Zentiva: Prague-headquartered pan-European generics and specialty pharma company with strong CEE presence; overlaps with ExCEEd Orphan on regional pharma distribution and market-access services.
- Gedeon Richter: Hungary-headquartered mid-cap pharma with deep CEE distribution footprint and growing specialty/rare-disease exposure; relevant comparable for CEE-centric pharma distribution scale.
- Egis Pharmaceuticals: CEE-focused pharmaceutical company with broad portfolio across CEE markets; provides a comparable for regional pharma distribution and market-access operations.
Market position
Customer concentration
ExCEEd Orphan financial estimates
Financial estimateRevenue estimate
Valuation estimate
ExCEEd Orphan leadership team
Management profileNumber of profiles
ExCEEd Orphan funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ExCEEd Orphan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ExCEEd Orphan
What does ExCEEd Orphan do?
ExCEEd Orphan performs multiple successful launches of rare disease medications (orphan drugs) in Central & Eastern European countries. The company provides specialized regional distribution and pharmacovigilance / drug safety services to support orphan drug commercialization across the CEE region, acting as a niche market-entry and lifecycle partner for pharmaceutical manufacturers of rare disease therapies.
Is ExCEEd Orphan a public or private company?
ExCEEd Orphan is a private company. It is classified as unknown and is currently operating.
When was ExCEEd Orphan founded?
ExCEEd Orphan was founded in 2018. It employs 11 to 50 people.
Where is ExCEEd Orphan based?
ExCEEd Orphan is headquartered in Prague, Czechia, in the Europe region.
Who are ExCEEd Orphan's main competitors?
Direct peers on record are Swedish Orphan Biovitrum (SOBI) and Recordati Rare Diseases (Orphan Europe). Broad incumbents are BioMarin Pharmaceutical and Alexion (AstraZeneca Rare Disease). Emerging players are Ultragenyx Pharmaceutical and Dipharma. Regional players are Polpharma, Zentiva, Gedeon Richter and Egis Pharmaceuticals.
Does ExCEEd Orphan have an API?
No public API is recorded for ExCEEd Orphan.
What industry is ExCEEd Orphan in?
ExCEEd Orphan's product category is Orphan Drug Distribution & Pharmacovigilance Services. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 32541 and its SIC code is 2834.